Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Hum Immunol. 2013 Aug;74(8):899-906. doi: 10.1016/j.humimm.2013.04.017. Epub 2013 Apr 30.
Chronic systemic 'latent' viral infections such as Cytomegalovirus infection (CMV) are known to leave a fingerprint in the total T-cell population. We investigated whether chronic infections with a 'persistent' viremia, such as chronic hepatitis B and C (CHB, CHC), characterized by local organ-specific inflammation, also impact the total peripheral T-cell population or other virus specific T-cells that do not target hepatitis viruses. No phenotypic or functional differences were found between CD8(+) T-cells or CMV- or Epstein-Barr virus specific T-cells in viral hepatitis and healthy controls (HC). However, expression of chemokine-receptor CXCR3 was significantly higher on total peripheral CD8(+) T-cells of CHB or CHC patients compared to HC (p<0.005) which may reflect the pervasive influence of a persistent viral infection, even when restricted to the liver. In CHB higher CXCR3 expression was associated with positive HBeAg-status and correlated with the percentage of HBsAg expressing hepatocytes found in liver biopsies, both pointing to a relation between CXCR3 expression and disease activity. In fact chemokine-receptors such as CXCR3 are important for T-cell recruitment to the liver and chemokine-ligands specific for CXCR3 are upregulated in chronic hepatitis. Modulating chemokine(receptor) expression could be a potential target for future therapy to optimize the anti-viral immunologic environment in the liver.
慢性全身性“潜伏”病毒感染,如巨细胞病毒感染(CMV),已知会在总 T 细胞群体中留下痕迹。我们研究了是否慢性感染具有“持续性”病毒血症,如慢性乙型肝炎和丙型肝炎(CHB、CHC),其特征为局部器官特异性炎症,也会影响总外周 T 细胞群体或其他不针对肝炎病毒的特定病毒 T 细胞。在病毒性肝炎和健康对照组(HC)中,未发现 CD8(+)T 细胞或 CMV 或 Epstein-Barr 病毒特异性 T 细胞之间存在表型或功能差异。然而,与 HC 相比,CHB 或 CHC 患者的总外周 CD8(+)T 细胞上趋化因子受体 CXCR3 的表达显著更高(p<0.005),这可能反映出持续性病毒感染的普遍影响,即使局限于肝脏。在 CHB 中,较高的 CXCR3 表达与 HBeAg 阳性状态相关,并且与肝活检中发现的 HBsAg 表达肝细胞的百分比相关,这两者都指向 CXCR3 表达与疾病活动之间的关系。事实上,趋化因子受体如 CXCR3 对于 T 细胞向肝脏的募集很重要,并且趋化因子配体特异性地针对 CXCR3 在慢性肝炎中上调。调节趋化因子(受体)表达可能是未来治疗的一个潜在目标,以优化肝脏中的抗病毒免疫环境。